NAMS — NewAmsterdam Pharma NV Cashflow Statement
0.000.00%
Last trade - 00:00- $3.79bn
- $3.16bn
- $22.50m
Annual cashflow statement for NewAmsterdam Pharma NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.8 | -22.6 | -177 | -242 | -204 |
| Depreciation | |||||
| Non-Cash Items | 7.8 | 22.9 | 29.8 | 116 | 63.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.47 | 10.4 | 5.87 | -32.7 | -7.94 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -29.5 | 10.7 | -141 | -159 | -148 |
| Capital Expenditures | -0.024 | -0.221 | -0.024 | -0.672 | -0.246 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -62.2 | -175 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.024 | -0.221 | -0.024 | -62.8 | -175 |
| Financing Cash Flow Items | 0 | -5.79 | 0 | -1.53 | -1.59 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 84.7 | 392 | 8.91 | 660 | 29.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 50.5 | 408 | -127 | 431 | -280 |